The massive EPS beat is a one-time milestone event, not operational leverage. The real catalysts are the upcoming RGX-202 BLA submission (Q3 2026) and pivotal wet AMD data (Q4 2026). Monitor for regulatory updates and data readouts, which will determine the stock's trajectory beyond this quarter's cash infusion.
Price Chart
Executive Summary
REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a $100M AbbVie milestone payment. Revenue surged to $108.0M from $21.4M YoY, but this was entirely milestone-driven; core operations remain loss-making. The company raised $108M in a July offering and ended Q2 with pro-forma cash of ~$313M, extending runway into Q4 2027. Key catalysts include RGX-202 BLA submission in Q3 2026 and pivotal wet AMD data in Q4 2026.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus -$0.11, a 499% beat.
- Revenue of $108.0M was driven by a $100M AbbVie milestone payment for dosing first patient in NAAVIGATE study.
- Pro-forma cash, cash equivalents and marketable securities of ~$313M as of June 30, 2026, extending runway into Q4 2027.
- Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint with high statistical significance (p<0.0001).
- BLA submission for RGX-202 on track for Q3 2026 under accelerated approval pathway.
- Topline data from pivotal subretinal wet AMD studies (ATMOSPHERE and ASCENT) expected in Q4 2026.
- RGX-121 BLA resubmission for Hunter syndrome on track for Q3 2026 after positive FDA Type A meeting.
- ZOLGENSMA royalty revenues decreased by $16.7M due to U.S. patent expiration in January 2026.
- R&D expenses decreased to $56.1M from $59.5M YoY.
- General and administrative expenses increased to $21.6M from $19.9M YoY.
Financial Impact
Q2 revenue of $108.0M (vs $21.4M YoY) driven by $100M milestone; GAAP net income of $22.7M vs net loss of $70.9M YoY; pro-forma cash ~$313M
Risk Factors
- Revenue is heavily dependent on milestone payments and partnership royalties, not product sales.
- ZOLGENSMA royalty decline from patent expiration creates a headwind to baseline revenue.
- Clinical trial failures or regulatory delays for RGX-202, sura-vec, or RGX-121 could impair the pipeline's value.
- Dilution from the July 2026 public offering increases share count.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336716 |
| Document: 0001193125-26-336716-index.html | 0001193125-26-336716 |
| Document: 0001193125-26-336716.txt | 0001193125-26-336716 |
| 8-K Data (Synthetic) | 0001193125-26-336716 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access